Skip to main content

Maka S. Hedrington, MD

Academic Title:

Assistant Professor

Primary Appointment:

Medicine

Education and Training

  • Master of Business Administration, University of Maryland University College, Baltimore, MD, 2014
  • Medical Doctor, Aieti Medical School, Tbilisi, Georgia
  • Postdoctoral Fellowship. Division of Diabetes, Endocrinology, Metabolism. Vanderbilt University, Nashville, TN. Mentor: Stephen N Davis, MBBS
  • Job Shadowing. Thedacare Hospital System, Appleton, WI
  • Internship/Specialty Training. Pediatric Cardiology. Jo Ann Medical Center. Tbilisi, Georgia. Mentor: Vakhtang Khelashvili, MD

Biosketch

Maka S Hedrington, MD, MBA, is a graduate of Aieti Medical School. She trained in cardiology at Jo Ann Medical Center in Tbilisi, Georgia and completed a postdoctoral research fellowship at Vanderbilt University in Nashville, TN. She is also a 2013 Phi Kappa Phi graduate of the University of Maryland University College Master in Business Administration program.

In December 2009 Maka joined the faculty of the University of Maryland. She works in a diabetes lab and investigates mechanisms that defend against hypoglycemia (low blood sugar). Some of the projects she has been working on are: (1) How different levels of hypoglycemia affect the blood vessels; (2) How the selective serotonin re-uptake inhibitor, fluoxetine (Prozac), an antidepressant often used to treat depression, affects body’s ability to defend itself from hypoglycemia that can occur during or after exercise; (3) How alprazolam (Xanax), an anti-anxiety drug, affects specialized molecules in the brain called GABA (A) receptors that alter the body’s ability to defend itself from hypoglycemia.

Maka has published over 15 original and review articles and has also served as a peer reviewer.

Research/Clinical Keywords

Type 1 diabetes, GABA, exercise, hypoglycemia, xanax, fluoxetine

Highlighted Publications

  • Hedrington MS, Mikeladze M, Tate DB, Younk LM, Davis I, Davis SN. Effect of GABA A receptor activation on counterregulatory responses to subsequent exercise in individuals with type 1 diabetes. Diabetes. 2016.
  • Hedrington MS, Tate DB, Younk LM, Davis SN. Effect of antecedent GABA A receptor activation on counterregulatory responses to exercise in healthy man. Diabetes. 2015 Apr 21. doi:pii: db150212. PMID: 25901095
  • Hedrington MS, Farmerie S, Tate DB, Ertl AC and Davis SN. The Effects of GABAA Activation on Subsequent Counterregulatory Responses to Hypoglycemia in Healthy Man. Diabetes. 2010 Apr;59(4):1074-81

Additional Publication Citations

  • Mikeladze M, Hedrington MS, Joy N, Tate DB, Younk LM, Davis I, et al. Acute Effects of Oral Dehydroepiandrosterone on Counterregulatory Responses During Repeated Hypoglycemia in Healthy Humans. Diabetes. 2016;65(10):3161-70.
  • Hedrington MS, Davis SN. Safety of the Dipeptidyl Peptidase-4 Inhibitors. Current Drug Safety. In manuscript.
  • Hedrington MS, Davis SN. The role of empagliflozin in the management of type 2 diabetes by patient profile. Therapeutics and Clinical Risk Management. 2015:11. DOI http://dx.doi.org/10.2147/TCRM.S71762
  • Hedrington MS and Davis SN. Sexual dimorphism in glucose and lipid metabolism during fasting, hypoglycemia and exercise. Front. Endocrinol. 6:61. doi: 10.3389/fendo.2015.00061
  • Hedrington MS, Davis SN.Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.Expert Opin Drug Metab Toxicol. 2015 Feb 2:1-11
  • Hedrington MS, Davis SN. Discontinued in 2013: diabetic drugs.Expert Opin Investig Drugs. 2014 Sep 24:1-9.
  • Davis SN, Tate DB, Hedrington MS. Mechanisms of hypoglycemia and exercise associated autonomic dysfunction. Transactions of the American clinical and climatological association, vol. 125, 2014
  • Lisa M Younk, Maka S Hedrington and Stephen N Davis. Hypoglycemia associated with exercise in diabetes. Diabetic Hypoglycemia October 2011, Volume 4, Issue 2: page 3-10
  • Hedrington MS, Pulliam L, Davis SN. Basal insulin treatment in type 2 diabetes. Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S33-42.
  • Wang Z, Hedrington MS, Gogitidze Joy N, Briscoe VJ, Richardson MA, Younk L, Nicholson W, Tate DB, Davis SN. Physiologic dose response effects of insulin glargine in type 2 diabetes. Diabetes Care July 2010 33:1555-1560
  • Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB and Davis SN.  The effects of hypoglycemia on atherothrombotic balance in type 1 DM and healthy man.  Diabetes Care July 2010 33:1529-1535